News/ News/ R&D AbbVie adds to Vraylar data as FDA considers depression use Phil Taylor AbbVie, depression, Psychiatry, Vraylar 0 Comment AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, Share X AbbVie adds to Vraylar data as FDA considers depression use https://pharmaphorum.com/news/abbvie-adds-to-vraylar-data-as-fda-considers-depression-use/
Market Access/ News/ News AbbVie files Vraylar as add-on therapy for depression in US Phil Taylor AbbVie, depression, Psychiatry, regulatory, Vraylar 0 Comment AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include Share X AbbVie files Vraylar as add-on therapy for depression in US https://pharmaphorum.com/news/abbvie-files-vraylar-as-add-on-therapy-for-depression-in-us/
